Immunogen Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for IMGN after Its Q1 Results

    On May 15, Immunogen (IMGN) issued a press release announcing mature data from its FORWARD II expansion cohort.

    By Margaret Patrick
  • uploads///test _
    Company & Industry Overviews

    Why Immunogen Was Down by More than 30% on May 15

    On May 15, Immunogen (IMGN) issued a press release announcing the FDA’s recommendation to conduct a new Phase 3 trial.

    By Margaret Patrick
  • uploads///Collaboration
    Company & Industry Overviews

    Behind Jazz’s Strategic Collaboration with ImmunoGen

    In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.

    By Daniel Collins
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Immunogen Topped the Small-Cap Stocks with High Volumes

    Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Ultragenyx: A Top Loser in the Biotechnology Subgroup

    Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.